3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
39
Ovarian Neoplasms
32
Triple Negative Breast Neoplasms
19
Prostatic Neoplasms
17
Fallopian Tube Neoplasms
16
Neoplasm Metastasis
14
Pancreatic Neoplasms
9
Neoplasms
9
Endometrial Neoplasms
9
Carcinoma, Non-Small-Cell Lung
7
Small Cell Lung Carcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Glioma
6
Stomach Neoplasms
5
Sarcoma
5
Lung Neoplasms
5
Glioblastoma
5
Squamous Cell Carcinoma of Head and Neck
4
Metastatic Castration-resistant Prostate Cancer
4
Carcinoma, Ovarian Epithelial
4
Solid Tumors
3
Recurrence
3
Osteosarcoma
3
Neuroendocrine Tumors
3
Lymphoma, Non-Hodgkin
3
Cholangiocarcinoma
3
Urinary Bladder Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Interventions
pembrolizumab
59
Cisplatin
45
Cetuximab
29
Radiotherapy
26
Carboplatin
24
Docetaxel
17
Paclitaxel
16
Nivolumab
16
Surveys and Questionnaires
15
Radiotherapy, Intensity-Modulated
13
Fluorouracil
12
Drug Therapy
12
Blood Specimen Collection
11
Standard of Care
8
tislelizumab
7
cemiplimab
6
atezolizumab
6
Radiation
6
Chemoradiotherapy
6
toripalimab
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
nimotuzumab
4
fludarabine
4
durvalumab
4
dostarlimab
4
Surgical Procedures, Operative
4
Afatinib
4
palbociclib
3
niraparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
olaparib
×
1 year
×
Clear all
NCT02308072
2026-05-22
ORCA-2
University College, London
Phase 1
Completed
16 enrolled